Cargando…

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

INTRODUCTION: Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted. METHODS: The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the CAM. Modelled patients were 280 adults wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mankinen, Petri, Lundström, Tuomas, Soini, Erkki, Sumelahti, Marja-Liisa, Ruutiainen, Juhani, Niskala, Ulla, Järvinen, Elina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999169/ https://www.ncbi.nlm.nih.gov/pubmed/31873868 http://dx.doi.org/10.1007/s12325-019-01186-z

Ejemplares similares

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
por: Järvinen, Elina, et al.
Publicado: (2019)

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness
por: Järvinen, Elina, et al.
Publicado: (2016)

Validation of the Finnish version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and evaluation of the applicability of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and the Fatigue Scale for Motor and Cognitive Functions (FSMC)
por: Hämäläinen, Päivi, et al.
Publicado: (2021)

Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland
por: Puolitaival, Antti, et al.
Publicado: (2022)

Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management
por: Soini, Erkki, et al.
Publicado: (2018)

Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale‐29
por: Rosti‐Otajärvi, Eija, et al.
Publicado: (2017)

Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients
por: Rosti‐Otajärvi, Eija, et al.
Publicado: (2017)

Research on lower extremity health in patients with multiple sclerosis: a systematic scoping review
por: Stolt, Minna, et al.
Publicado: (2020)

Diffusion tensor imaging and disability progression in multiple sclerosis: A 4‐year follow‐up study
por: Kolasa, Marcin, et al.
Publicado: (2018)

Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2014)

Medical students’ experience of emotions and success in neurological studies – What do they tell us?
por: Ansakorpi, Hanna, et al.
Publicado: (2017)

Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981–2010
por: Holmberg, Markus, et al.
Publicado: (2013)

Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study
por: Järvinen, Elina, et al.
Publicado: (2017)

Cost of managing an episode of relapse in multiple sclerosis in the United States
por: O'Brien, Judith A, et al.
Publicado: (2003)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
por: Nicholas, Jacqueline, et al.
Publicado: (2020)

Stroke and cardiovascular risk factors among working-aged Finnish migraineurs
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2021)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis
por: Giedraitiene, Natasa, et al.
Publicado: (2018)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
por: Caster, Ola, et al.
Publicado: (2015)

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
por: Soini, Erkki J., et al.
Publicado: (2015)

Family Members’ Experiences of Maintaining an Older Relative’s Functional Ability in Long-Term Care
por: Lehto-Niskala, Vilhelmiina, et al.
Publicado: (2020)

Family's role in long‐term care—A qualitative study of Finnish family members' experiences on supporting the functional ability of an older relative
por: Lehto‐Niskala, Vilhelmiina, et al.
Publicado: (2021)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
por: Chevalier, Julie, et al.
Publicado: (2016)

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2020)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Assessing cost-effectiveness in the management of multiple sclerosis
por: Phillips, Ceri J, et al.
Publicado: (2009)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Assessing Relapse in Multiple Sclerosis Questionnaire: Results of a Pilot Study
por: Perrin Ross, Amy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k8meefqad3lh6j7pdcsd2mfqla